News Key drug in Sanofi's $1.45bn Kymab buyout shows promise in e... Already a major player in atopic dermatitis with Dupixent, Sanofi looked to expand its position in the category earlier this year when it
News Amgen pays Kyowa $400m upfront for OX40 eczema drug Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopi
News Neuralink gets okay for its first international trial Elon Musk's brain-computer interface (BCI) company Neuralink has been given the green light to test its device in tetraplegic patients in Canada
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends